Market By System, Application, And Geography | Forecast 2019-2027
According to Triton, the research on the Europe neurostimulation device market is estimated to record a significant growth at a CAGR of 9.58% over the forecast period 2019-2027.
Countries that are studied in Europe’s neurostimulation device market are:
• The United Kingdom
• France
• Germany
• Spain
• Italy
• Russia
• Rest of Europe
Report scope can be customized per your requirements. Request For Customization
The increase in the number of individuals affected by chronic pain, emerging public awareness, and coverage of neurostimulation devices are driving the market growth in Europe. Moreover, the coverage of neurostimulation devices and the rise in public awareness and are also fueling the market growth. According to the World Health Organization (WHO), around 3 million individuals suffer from epilepsy and over 150,000 new cases are diagnosed per year, which is expected to result in the adoption of neurostimulation devices. Additionally, the clinical evidence of neurostimulation devices is likely to increase when compared to drug therapy during the forecasted period.
Germany is predicted to grow with the highest CAGR over the forecasting years. There is an increasing prevalence of depression among adolescents. According to Barmer, a German health insurance company, about 470,000 German students have been suffering from mental disorders. This has led to the growth in health expenses for the treatment of these diseases and is offering lucrative opportunities to propel the neurostimulation device market growth.
In Spain, the demand for neurostimulation devices is anticipated to rise due to the high pervasiveness of Alzheimer’s disease. The country is making efforts to improve the overall quality of life of the patients. This would help them to return to their highest level of function and independence, thereby boosting the adoption of neurostimulation devices in the country.
Hocoma AG is a global company that designs, manufactures, develops, and commercializes automated therapy equipment for the rehabilitation of patients suffering from neurological movement disorders. The company offers a wide range of products that are used to treat neurological patients with movement disorders caused by stroke, multiple sclerosis, spinal cord injury, traumatic brain injury, and various neurological diseases. The company operates in Europe, North and Latin America, Asia-Pacific, and the Middle East and Africa.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
NEUROSTIMULATION DEVICE MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCES MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF SUPPLIERS
2.2.4. BARGAINING
POWER OF BUYERS
2.2.5. THREAT
OF RIVALRY
2.3. VALUE
CHAIN OUTLOOK
2.4. MARKET
TRENDS
2.5. MARKET
SHARE OUTLOOK
2.6. PESTLE
OUTLOOK
2.7. MARKET
ATTRACTIVENESS INDEX
2.8. KEY
INSIGHT
2.9. MARKET
DRIVERS
2.9.1. RISING
INCIDENCE OF NEURO DISEASES
2.9.2. INCREASING
GERIATRIC POPULATION
2.9.3. GROWING
DEMAND FOR MRI SCANS
2.9.4. FAVORABLE
REIMBURSEMENT POLICIES
2.10.
MARKET RESTRAINTS
2.10.1.
HIGH COST OF NEUROMODULATION TREATMENT
2.10.2.
PRESENCE OF ALTERNATIVE THERAPY
2.11.
MARKET OPPORTUNITIES
2.11.1.
HIGH MARKET POTENTIAL FOR SCS DEVICES IN
NEUROSTIMULATION
2.11.2.
TECHNOLOGICAL DEVELOPMENT
2.11.3.
GROWING INCIDENCE OF CHRONIC DISCOMFORT
2.12.
MARKET CHALLENGES
2.12.1.
STRINGENT REGULATORY APPROVALS
2.12.2.
SIDE EFFECTS OF ASSOCIATED NEUROSTIMULATION
DEVICES
3. NEUROSTIMULATION
DEVICE MARKET OUTLOOK – BY SYSTEM
3.1. SPINAL
CORD STIMULATORS (SCS)
3.2. DEEP
BRAIN STIMULATORS (DBS)
3.3. SACRAL
NERVE STIMULATORS (SNS)
3.4. VAGUS
NERVE STIMULATORS (VNS)
3.5. GASTRIC
ELECTRIC STIMULATOR
3.6. OTHER
SYSTEM
4. NEUROSTIMULATION
DEVICE MARKET OUTLOOK – BY APPLICATIONS
4.1. PAIN
MANAGEMENT
4.2. EPILEPSY
4.3. ESSENTIAL
TREMOR
4.4. URINARY
AND FECAL INCONTINENCE
4.5. DEPRESSION
4.6. DYSTONIA
4.7. GASTROPARESIS
4.8. PARKINSON’S
DISEASE
4.9. OTHER
APPLICATIONS
5. NEUROSTIMULATION
DEVICE MARKET – REGIONAL OUTLOOK
5.1.1. COUNTRY
ANALYSIS
5.1.1.1. THE
UNITED KINGDOM
5.1.1.2. FRANCE
5.1.1.3. GERMANY
5.1.1.4. SPAIN
5.1.1.5. ITALY
5.1.1.6. RUSSIA
5.1.1.7. REST
OF EUROPE
6. COMPANY
PROFILES
6.1. NEURONETICS,
INC.
6.2. ST.
JUDE MEDICAL, INC. (ACQUIRED BY ABBOTT LABORATORIES)
6.3. HOCOMA
AG
6.4. NEVRO
CORP.
6.5. CYBERONICS
INC.
6.6. COGENTIX
MEDICAL, INC.
6.7. DEPUY
SYNTHES COMPANIES
6.8. DR.
LANGER MEDICAL GMBH
6.9. MEDTRONIC
PLC
6.10.
THE MAGSTIM COMPANY LIMITED
6.11.
ECTRON LIMITED
6.12.
BOSTON SCIENTIFIC CORPORATION
6.13.
EKSO BIONICS HOLDING INC.
6.14.
ALEVA NEUROTHERAPEUTICS SA
6.15.
HELIUS MEDICAL TECHNOLOGIES
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.1.1. OBJECTIVES
OF STUDY
7.1.2. SCOPE
OF STUDY
7.2. SOURCES
OF DATA
7.2.1. PRIMARY
DATA SOURCES
7.2.2. SECONDARY
DATA SOURCES
7.3. RESEARCH
METHODOLOGY
7.3.1. EVALUATION
OF PROPOSED MARKET
7.3.2. IDENTIFICATION
OF DATA SOURCES
7.3.3. ASSESSMENT
OF MARKET DETERMINANTS
7.3.4. DATA
COLLECTION
7.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1 EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
TABLE 2 EUROPE NEUROSTIMULATION DEVICE MARKET BY SYSTEM 2019-2027 ($
MILLION)
TABLE 3 EUROPE NEUROSTIMULATION DEVICE MARKET BY APPLICATIONS
2019-2027 ($ MILLION)
TABLE 4 EUROPE NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($
MILLION)
FIGURE 1 EUROPE NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 2 VALUE CHAIN OUTLOOK
FIGURE 3 NEUROSTIMULATION DEVICE COMPANY MARKET
SHARE OUTLOOK 2018 (%)
FIGURE 4 EUROPE NEUROSTIMULATION DEVICE MARKET BY
SPINAL CORD STIMULATORS 2019-2027 ($ MILLION)
FIGURE 5 EUROPE NEUROSTIMULATION DEVICE MARKET BY
DEEP BRAIN STIMULATORS 2019-2027 ($ MILLION)
FIGURE 6 EUROPE NEUROSTIMULATION DEVICE MARKET BY
SACRAL NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 7 EUROPE NEUROSTIMULATION DEVICE MARKET BY
VAGUS NERVE STIMULATORS 2019-2027 ($ MILLION)
FIGURE 8 EUROPE NEUROSTIMULATION DEVICE MARKET BY
GASTRIC ELECTRIC STIMULATOR 2019-2027 ($ MILLION)
FIGURE 9 EUROPE NEUROSTIMULATION DEVICE MARKET BY
OTHER SYSTEM 2019-2027 ($ MILLION)
FIGURE 10 EUROPE NEUROSTIMULATION DEVICE MARKET BY PAIN
MANAGEMENT 2019-2027 ($ MILLION)
FIGURE 11 EUROPE NEUROSTIMULATION DEVICE MARKET BY
EPILEPSY 2019-2027 ($ MILLION)
FIGURE 12 EUROPE NEUROSTIMULATION DEVICE MARKET BY
ESSENTIAL TREMOR 2019-2027 ($ MILLION)
FIGURE 13 EUROPE NEUROSTIMULATION DEVICE MARKET BY
URINARY AND FECAL INCONTINENCE 2019-2027 ($ MILLION)
FIGURE 14 EUROPE NEUROSTIMULATION DEVICE MARKET BY
DEPRESSION 2019-2027 ($ MILLION)
FIGURE 15 EUROPE NEUROSTIMULATION DEVICE MARKET BY
DYSTONIA 2019-2027 ($ MILLION)
FIGURE 16 EUROPE NEUROSTIMULATION DEVICE MARKET BY
GASTROPARESIS 2019-2027 ($ MILLION)
FIGURE 17 EUROPE NEUROSTIMULATION DEVICE MARKET BY
PARKINSON’S DISEASE 2019-2027 ($ MILLION)
FIGURE 18 EUROPE NEUROSTIMULATION DEVICE MARKET BY
OTHER APPLICATIONS 2019-2027 ($ MILLION)
FIGURE 19 THE UNITED KINGDOM NEUROSTIMULATION DEVICE
MARKET 2019-2027 ($ MILLION)
FIGURE 20 FRANCE NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 21 GERMANY NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 22 SPAIN NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 23 ITALY NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 24 RUSSIA NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)
FIGURE 25 REST OF EUROPE NEUROSTIMULATION DEVICE MARKET
2019-2027 ($ MILLION)